Tirzepatide
| Generic name: | Tirzepatide |
| Cas No.: | 2023788-19-2 |
| Molecular Formula: | C225H348N48O68 |
| Molecular weight: | 4813.45 g/mol |
| Sequence: | H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Appearance: | White powder |
| Application: | Tirzepatide is a drug being studied for its potential use in treating type 2 diabetes. It belongs to a class of drugs called diglucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Tezepatide works by stimulating GIP and GLP-1 receptors in the body. These receptors play an important role in regulating blood sugar levels and metabolism. By activating these receptors, tezepatide increases the production of insulin and decreases the secretion of glucagon, a hormone that raises blood sugar levels. It also slows gastric emptying and helps regulate blood sugar levels. Clinical trials have shown that tilsiparatide can effectively control blood sugar levels in patients with type 2 diabetes. It has also been found to promote weight loss, which is an added benefit for many people with type 2 diabetes who have difficulty maintaining a healthy weight. One of the advantages of tezeparatide is its once-weekly dosing regimen, which may increase convenience and compliance with the treatment regimen. This may be particularly beneficial for individuals who have difficulty adhering to a daily medication schedule or who prefer a more streamlined treatment plan. It should be noted that tilsiparatide is still in the investigational stage and has not yet been approved for use by regulatory agencies. Further research is needed to determine its long-term safety and effectiveness and to identify any potential side effects. In summary, tilsiparatide is a new drug being investigated for the treatment of type 2 diabetes. Its dual action on GIP and GLP-1 receptors has the potential to improve glycemic control and weight loss. However, more research is needed before tilsiparatide can be recommended as a treatment option for people with type 2 diabetes. |
| Package: | aluminium foil bag or aluminium TIN or as per customer’s requirements |
|
1 |
Professional supplier for peptide APIs from China. |
|
2 |
16 production lines with enough big production capacity with competitive price |
|
3 |
DMF available with most reliable documentation. |
A: Yes, we can pack as your requirement.
A: LC sight and TT in advance payment term preferred.
A: Yes, please provide your quality specification, we will check with our R&D and try to match your quality specification.
Write your message here and send it to us
